Literature DB >> 16388428

Streptococcus pneumoniae: epidemiology, risk factors, and clinical features.

Ake Ortqvist1, Jonas Hedlund, Mats Kalin.   

Abstract

Streptococcus pneumoniae is the most common cause of both pneumonia overall and fatal pneumonia. Antibiotic resistance has developed worldwide and is most frequent in pneumococcal serotypes that are most prevalent in children (types/groups 6, 14, 19, and 23). The incidence of pneumococcal disease is the highest in children < 2 years of age and in adults > 65 years of age. Other important risk factors are chronic heart and lung disease, cigarette smoking, and asplenia. A 23-valent capsular polysaccharide vaccine and a heptavalent protein-polysaccharide conjugate vaccine are currently available. The latter is specially designed for pediatric use because small children respond poorly to polysaccharide antigens. Both vaccines are efficacious in prevention of invasive pneumococcal disease. The clinical presentation of pneumococcal pneumonia is variable, and neither clinical features nor laboratory or radiographic findings can reliably predict the etiology of pneumonia. Blood culture is the most important tool for establishing a definitive diagnosis, but Gram's stains and sputum culture are also of value in skilled hands. A recently developed urinary antigen test may provide a rapid diagnosis of pneumococcal pneumonia in adults. Penicillin (penicillin G/amoxicillin) remains the drug of choice for strains that are fully sensitive or have a moderately decreased susceptibility to penicillin, whereas cefotaxime and ceftriaxone are the first-line alternatives in cases with higher levels of resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16388428     DOI: 10.1055/s-2005-925523

Source DB:  PubMed          Journal:  Semin Respir Crit Care Med        ISSN: 1069-3424            Impact factor:   3.119


  62 in total

1.  Local delivery of GM-CSF protects mice from lethal pneumococcal pneumonia.

Authors:  Kathrin Steinwede; Ole Tempelhof; Kristine Bolte; Regina Maus; Jennifer Bohling; Bianca Ueberberg; Florian Länger; John W Christman; James C Paton; Kjetil Ask; Shyam Maharaj; Martin Kolb; Jack Gauldie; Tobias Welte; Ulrich A Maus
Journal:  J Immunol       Date:  2011-10-14       Impact factor: 5.422

Review 2.  Role of pore-forming toxins in bacterial infectious diseases.

Authors:  Ferdinand C O Los; Tara M Randis; Raffi V Aroian; Adam J Ratner
Journal:  Microbiol Mol Biol Rev       Date:  2013-06       Impact factor: 11.056

3.  [Bacteriologic profile and drug resistance in children with respiratory infection from 2016 to 2018].

Authors:  Qian-Yu Wang; Cong-Rong Li; Jing Guo; Ke-Wen Tang
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2019-12

4.  Cigarette smoke exposure worsens acute lung injury in antibiotic-treated bacterial pneumonia in mice.

Authors:  Jeffrey E Gotts; Lauren Chun; Jason Abbott; Xiaohui Fang; Naoki Takasaka; Stephen L Nishimura; Matthew L Springer; Suzaynn F Schick; Carolyn S Calfee; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-03-15       Impact factor: 5.464

5.  A novel ketolide, RBx 14255, with activity against multidrug-resistant Streptococcus pneumoniae.

Authors:  V Samuel Raj; Tarani Kanta Barman; Vandana Kalia; Kedar Purnapatre; Smita Dube; Ramkumar G; Pragya Bhateja; Tarun Mathur; Tridib Chaira; Dilip J Upadhyay; Yogesh B Surase; R Venkataramanan; Anjan Chakrabarti; Biswajit Das; Pradip K Bhatnagar
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

Review 6.  Multidrug-resistant Streptococcus pneumoniae infections: current and future therapeutic options.

Authors:  Françoise Van Bambeke; René R Reinert; Peter C Appelbaum; Paul M Tulkens; Willy E Peetermans
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

8.  Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar; Jorge A Guzmán; Teresa Rodriguez-Blanco; Elisabet Salsench; Cruz M Fuentes
Journal:  BMC Infect Dis       Date:  2010-03-18       Impact factor: 3.090

9.  The development of a 16S rRNA gene based PCR for the identification of Streptococcus pneumoniae and comparison with four other species specific PCR assays.

Authors:  Nabil Abdullah El Aila; Stefan Emler; Tarja Kaijalainen; Thierry De Baere; Bart Saerens; Elife Alkan; Pieter Deschaght; Rita Verhelst; Mario Vaneechoutte
Journal:  BMC Infect Dis       Date:  2010-04-29       Impact factor: 3.090

10.  Pneumococcal sepsis presenting as acute compartment syndrome of the lower limbs: a case report.

Authors:  Sudeendra Doddi; Tarun Singhal; Prakash Sinha
Journal:  J Med Case Rep       Date:  2009-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.